ARTV Stock — Artiva Biotherapeutics, Inc.: Metrics

Market overview

2 metrics

Share price

$11.28

Market cap

$552.95M

Price action

19 metrics

Price change (1W)

-4.2%

Price change (30D)

+4.8%

Price change (3M)

+64.2%

Price change (6M)

+106.2%

Price change (YTD)

+162.9%

Price change (1Y)

+258.1%

Trailing year

Price change (5Y)

—

52-week high

$13.39

52-week low

$2.28

Change from 52-week high

-15.8%

Change from 52-week low

+394.7%

Annualized volatility

183.9%

Beta

2.1

RSI (14D)

52.3

Price vs SMA 50

+7.9%

Price vs SMA 200

+54.7%

Avg volume (3M)

477,113

Relative volume

0.6

Average dollar volume

$4.58M

Company

3 metrics

Sector

Healthcare

Industry

Biotechnology

Shares outstanding

48.89M

Valuation

12 metrics

P / E (TTM)

—

Trailing earnings

PEG ratio

—

EV / revenue

—

EV / EBITDA

—

EV / EBIT

—

P / sales

212.4×

reciprocal yield 0.5%

P / book

1.6

reciprocal yield 62.9%

FCF yield

-13.9%

TTM · current market cap

Buyback yield

—

P / FCF

—

P / operating cash flow

—

Earnings yield

-16.4%

Historical valuation

8 metrics

P / E historical average (3Y)

—

P / E historical average (5Y)

—

EV / revenue historical average (3Y)

—

EV / revenue historical average (5Y)

—

EV / EBIT historical average (3Y)

—

EV / EBIT historical average (5Y)

—

EV / EBITDA historical average (3Y)

—

EV / EBITDA historical average (5Y)

—

Dividends & buybacks

7 metrics

Dividend yield

—

Trailing 12 months

Payout ratio

—

Shareholder yield

—

Dividend / share (TTM)

—

Dividend growth YoY

—

Dividend growth streak

—

Last ex-dividend

—

Earnings calendar

2 metrics

Next earnings

—

Last earnings

2026-06-08

Profitability

9 metrics

Gross margin

—

Operating margin

—

Trailing 12 months

Net margin

—

Gross profit (TTM)

—

Operating profit (TTM)

−$96.15M

Net income (TTM)

−$90.82M

Trailing 12 months

Diluted EPS (TTM)

$-3.31

FCF margin

—

Effective tax rate

—

Per share

11 metrics

Revenue per diluted share (TTM)

—

Gross profit per diluted share (TTM)

—

Operating profit per diluted share (TTM)

—

EBITDA per diluted share (TTM)

—

Net income per diluted share (TTM)

—

Operating cash flow per diluted share (TTM)

—

Free cash flow per diluted share (TTM)

—

Capital expenditures per diluted share (TTM)

—

R&D per diluted share (TTM)

—

Stock compensation per diluted share (TTM)

—

Book value per share

—

Growth

11 metrics

Revenue growth YoY

-100.0%

Year over year

Net income growth YoY

—

Revenue (TTM)

$2.60M

Trailing 12 months

EPS growth YoY

—

Shares change YoY

+61.7%

Year over year · more shares

Revenue CAGR (3Y)

—

Revenue CAGR (5Y)

—

EPS CAGR (3Y)

—

EPS CAGR (5Y)

—

FCF CAGR (3Y)

—

FCF CAGR (5Y)

—

Quality

14 metrics

Return on equity

-26.1%

Return on assets

-24.6%

Debt / equity

—

Current ratio

24.2

EBITDA (TTM)

−$93.46M

Free cash flow (TTM)

−$76.91M

Quick ratio

24.2

Interest coverage

—

Net debt / EBITDA

—

Return on invested capital

—

Trailing 12 months

Net cash

$349.39M

Latest balance sheet

Cash & equivalents

$301.45M

Total assets

$368.63M

Total debt

—

Cash flow & spend

7 metrics

Operating cash flow (TTM)

−$75.23M

Capital expenditures (TTM)

$1.68M

R&D (TTM)

$75.86M

SG&A (TTM)

—

Stock compensation (TTM)

$6.68M

R&D / revenue

—

Stock compensation / revenue

—

Ownership (13F)

3 metrics

13F filers

72

13F filer change QoQ

+32

Institutional ownership

82.6%

Short interest

3 metrics

Short interest

4.3%

Latest settlement · 6.1 days to cover

Days to cover

6.1d

Short-squeeze score

73 / 100

Insider activity

2 metrics

Net insider buying (90D)

$17.38M

Insider-sentiment score

92 / 100

Risk flags

1 metrics

Going concern

—

ARTV · Artiva Biotherapeutics, Inc.

ARTV metrics

Market overview

Price action

Company

Valuation

Historical valuation

Dividends & buybacks

Earnings calendar

Profitability

Growth

Quality

Cash flow & spend

Ownership (13F)

Short interest

Insider activity

Risk flags

No metrics match that search